351 related articles for article (PubMed ID: 17233589)
21. Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5'-phosphatase catalytic activity.
Wada T; Sasaoka T; Funaki M; Hori H; Murakami S; Ishiki M; Haruta T; Asano T; Ogawa W; Ishihara H; Kobayashi M
Mol Cell Biol; 2001 Mar; 21(5):1633-46. PubMed ID: 11238900
[TBL] [Abstract][Full Text] [Related]
22. Different roles of SHIP1 according to the cell context: the example of blood platelets.
Gratacap MP; Séverin S; Chicanne G; Plantavid M; Payrastre B
Adv Enzyme Regul; 2008; 48():240-52. PubMed ID: 18155171
[No Abstract] [Full Text] [Related]
23. Cell lines from kidney proximal tubules of a patient with Lowe syndrome lack OCRL inositol polyphosphate 5-phosphatase and accumulate phosphatidylinositol 4,5-bisphosphate.
Zhang X; Hartz PA; Philip E; Racusen LC; Majerus PW
J Biol Chem; 1998 Jan; 273(3):1574-82. PubMed ID: 9430698
[TBL] [Abstract][Full Text] [Related]
24. The structure and function of catalytic domains within inositol polyphosphate 5-phosphatases.
Whisstock JC; Wiradjaja F; Waters JE; Gurung R
IUBMB Life; 2002 Jan; 53(1):15-23. PubMed ID: 12018403
[TBL] [Abstract][Full Text] [Related]
25. The protein deficient in Lowe syndrome is a phosphatidylinositol-4,5-bisphosphate 5-phosphatase.
Zhang X; Jefferson AB; Auethavekiat V; Majerus PW
Proc Natl Acad Sci U S A; 1995 May; 92(11):4853-6. PubMed ID: 7761412
[TBL] [Abstract][Full Text] [Related]
26. The SH2 domains of inositol polyphosphate 5-phosphatases SHIP1 and SHIP2 have similar ligand specificity but different binding kinetics.
Zhang Y; Wavreille AS; Kunys AR; Pei D
Biochemistry; 2009 Nov; 48(46):11075-83. PubMed ID: 19839650
[TBL] [Abstract][Full Text] [Related]
27. The SH2 domain containing inositol 5-phosphatase SHIP2 displays phosphatidylinositol 3,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate 5-phosphatase activity.
Pesesse X; Moreau C; Drayer AL; Woscholski R; Parker P; Erneux C
FEBS Lett; 1998 Oct; 437(3):301-3. PubMed ID: 9824312
[TBL] [Abstract][Full Text] [Related]
28. Lowe syndrome, a deficiency of phosphatidylinositol 4,5-bisphosphate 5-phosphatase in the Golgi apparatus.
Suchy SF; Olivos-Glander IM; Nussabaum RL
Hum Mol Genet; 1995 Dec; 4(12):2245-50. PubMed ID: 8634694
[TBL] [Abstract][Full Text] [Related]
29. The role of SHIP1 in T-lymphocyte life and death.
Gloire G; Erneux C; Piette J
Biochem Soc Trans; 2007 Apr; 35(Pt 2):277-80. PubMed ID: 17371259
[TBL] [Abstract][Full Text] [Related]
30. SHIP family inositol phosphatases interact with and negatively regulate the Tec tyrosine kinase.
Tomlinson MG; Heath VL; Turck CW; Watson SP; Weiss A
J Biol Chem; 2004 Dec; 279(53):55089-96. PubMed ID: 15492005
[TBL] [Abstract][Full Text] [Related]
31. Reversible Ser/Thr SHIP phosphorylation: a new paradigm in phosphoinositide signalling?: Targeting of SHIP1/2 phosphatases may be controlled by phosphorylation on Ser and Thr residues.
Edimo WE; Janssens V; Waelkens E; Erneux C
Bioessays; 2012 Aug; 34(8):634-42. PubMed ID: 22641604
[TBL] [Abstract][Full Text] [Related]
32. The role of SHIP1 in macrophage programming and activation.
Rauh MJ; Sly LM; Kalesnikoff J; Hughes MR; Cao LP; Lam V; Krystal G
Biochem Soc Trans; 2004 Nov; 32(Pt 5):785-8. PubMed ID: 15494015
[TBL] [Abstract][Full Text] [Related]
33. The influence of anionic lipids on SHIP2 phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase activity.
Vandeput F; Backers K; Villeret V; Pesesse X; Erneux C
Cell Signal; 2006 Dec; 18(12):2193-9. PubMed ID: 16824732
[TBL] [Abstract][Full Text] [Related]
34. Structure and function of the Lowe syndrome protein OCRL1.
Lowe M
Traffic; 2005 Sep; 6(9):711-9. PubMed ID: 16101675
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer.
Fuhler GM; Brooks R; Toms B; Iyer S; Gengo EA; Park MY; Gumbleton M; Viernes DR; Chisholm JD; Kerr WG
Mol Med; 2012 Feb; 18(1):65-75. PubMed ID: 22033675
[TBL] [Abstract][Full Text] [Related]
36. Transcriptional profiling of C2C12 myotubes in response to SHIP2 depletion and insulin stimulation.
Huard C; Martinez RV; Ross C; Johnson JW; Zhong W; Hill AA; Kim R; Paulsen JE; Shih HH
Genomics; 2007 Feb; 89(2):270-9. PubMed ID: 17123777
[TBL] [Abstract][Full Text] [Related]
37. SHIP2 signalling at the plasma membrane, in the nucleus and at focal contacts.
Elong Edimo W; Vanderwinden JM; Erneux C
Adv Biol Regul; 2013 Jan; 53(1):28-37. PubMed ID: 23040614
[TBL] [Abstract][Full Text] [Related]
38. The 5-phosphatase OCRL in Lowe syndrome and Dent disease 2.
De Matteis MA; Staiano L; Emma F; Devuyst O
Nat Rev Nephrol; 2017 Aug; 13(8):455-470. PubMed ID: 28669993
[TBL] [Abstract][Full Text] [Related]
39. Serum withdrawal-induced accumulation of phosphoinositide 3-kinase lipids in differentiating 3T3-L6 myoblasts: distinct roles for Ship2 and PTEN.
Mandl A; Sarkes D; Carricaburu V; Jung V; Rameh L
Mol Cell Biol; 2007 Dec; 27(23):8098-112. PubMed ID: 17893321
[TBL] [Abstract][Full Text] [Related]
40. Regulation of FcgammaR-stimulated phagocytosis by the 72-kDa inositol polyphosphate 5-phosphatase: SHIP1, but not the 72-kDa 5-phosphatase, regulates complement receptor 3 mediated phagocytosis by differential recruitment of these 5-phosphatases to the phagocytic cup.
Horan KA; Watanabe K; Kong AM; Bailey CG; Rasko JE; Sasaki T; Mitchell CA
Blood; 2007 Dec; 110(13):4480-91. PubMed ID: 17682126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
